

SAFETY DATA SHEET



Losartan / Amlodipine Besylate Formulation



Version 3.11 Revision Date: 10.10.2020 SDS Number: 49927-00015 Date of last issue: 13.09.2019
Date of first issue: 26.01.2015

SECTION 1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Losartan / Amlodipine Besylate Formulation

Manufacturer or supplier's details

Company : Organon & Co.

Address : 30 Hudson Street, 33rd floor
Jersey City, New Jersey, U.S.A 07302

Telephone : 551-430-6000

Emergency telephone number : 215-631-6999

E-mail address : EHSSTEWARD@organon.com

Recommended use of the chemical and restrictions on use

Recommended use : Pharmaceutical

SECTION 2. HAZARDS IDENTIFICATION

GHS Classification

Serious eye damage/eye irritation : Category 1

Skin sensitisation : Category 1

Reproductive toxicity : Category 1B

Effects on or via lactation

Specific target organ toxicity - repeated exposure (Oral) : Category 2 (Blood, Cardio-vascular system, Stomach, Kidney)

GHS label elements

Hazard pictograms : 

Signal word : Danger

Hazard statements : H317 May cause an allergic skin reaction.
H318 Causes serious eye damage.
H360D May damage the unborn child.
H362 May cause harm to breast-fed children.
H373 May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

Precautionary statements : **Prevention:**

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	10.10.2020	49927-00015	Date of first issue: 26.01.2015

P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P260 Do not breathe dust.
P263 Avoid contact during pregnancy/ while nursing.
P264 Wash skin thoroughly after handling.
P270 Do not eat, drink or smoke when using this product.
P272 Contaminated work clothing should not be allowed out of the workplace.
P280 Wear protective gloves/ eye protection/ face protection.
P281 Use personal protective equipment as required.

Response:

P302 + P352 IF ON SKIN: Wash with plenty of soap and water.
P305 + P351 + P338 + P310 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER or doctor/ physician.
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P333 + P313 If skin irritation or rash occurs: Get medical advice/ attention.
P363 Wash contaminated clothing before reuse.

Storage:

P405 Store locked up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

Contact with dust can cause mechanical irritation or drying of the skin.
May form explosive dust-air mixture during processing, handling or other means.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Cellulose	9004-34-6	>= 60 -<= 100
Losartan	124750-99-8	>= 10 -< 30
Amlodipine Besylate	652969-01-2	< 10
Titanium dioxide	13463-67-7	< 1

SECTION 4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.

SAFETY DATA SHEET



Losartan / Amlodipine Besylate Formulation



Version 3.11 Revision Date: 10.10.2020 SDS Number: 49927-00015 Date of last issue: 13.09.2019
Date of first issue: 26.01.2015

- In case of skin contact : Get medical attention.
: In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.
Wash clothing before reuse.
Thoroughly clean shoes before reuse.
- In case of eye contact : In case of contact, immediately flush eyes with plenty of water for at least 15 minutes.
If easy to do, remove contact lens, if worn.
Get medical attention immediately.
- If swallowed : If swallowed, DO NOT induce vomiting.
Get medical attention.
Rinse mouth thoroughly with water.
- Most important symptoms and effects, both acute and delayed : May cause an allergic skin reaction.
Causes serious eye damage.
May damage the unborn child.
May cause harm to breast-fed children.
May cause damage to organs through prolonged or repeated exposure if swallowed.
Contact with dust can cause mechanical irritation or drying of the skin.
- Protection of first-aiders : First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).
- Notes to physician : Treat symptomatically and supportively.
-

SECTION 5. FIREFIGHTING MEASURES

- Suitable extinguishing media : Water spray
Alcohol-resistant foam
Carbon dioxide (CO₂)
Dry chemical
- Unsuitable extinguishing media : None known.
- Specific hazards during fire-fighting : Avoid generating dust; fine dust dispersed in air in sufficient concentrations, and in the presence of an ignition source is a potential dust explosion hazard.
Exposure to combustion products may be a hazard to health.
- Hazardous combustion products : Carbon oxides
Chlorine compounds
Nitrogen oxides (NO_x)
Metal oxides
- Specific extinguishing methods : Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
Use water spray to cool unopened containers.
Remove undamaged containers from fire area if it is safe to do so.
Evacuate area.
- Special protective equipment for firefighters : In the event of fire, wear self-contained breathing apparatus.
Use personal protective equipment.
-

SECTION 6. ACCIDENTAL RELEASE MEASURES

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	10.10.2020	49927-00015	Date of first issue: 26.01.2015

- Personal precautions, protective equipment and emergency procedures : Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).
- Environmental precautions : Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Retain and dispose of contaminated wash water. Local authorities should be advised if significant spillages cannot be contained.
- Methods and materials for containment and cleaning up : Sweep up or vacuum up spillage and collect in suitable container for disposal. Avoid dispersal of dust in the air (i.e., clearing dust surfaces with compressed air). Dust deposits should not be allowed to accumulate on surfaces, as these may form an explosive mixture if they are released into the atmosphere in sufficient concentration. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

SECTION 7. HANDLING AND STORAGE

- Technical measures : Static electricity may accumulate and ignite suspended dust causing an explosion. Provide adequate precautions, such as electrical grounding and bonding, or inert atmospheres.
- Local/Total ventilation : If sufficient ventilation is unavailable, use with local exhaust ventilation.
- Advice on safe handling : Avoid contact during pregnancy and while nursing. Do not get on skin or clothing. Do not breathe dust. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment. Keep container tightly closed. Minimize dust generation and accumulation. Keep container closed when not in use. Keep away from heat and sources of ignition. Take precautionary measures against static discharges. Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize release to the environment.
- Hygiene measures : If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Contaminated work clothing should not be allowed out of the

Losartan / Amlodipine Besylate Formulation

Version 3.11 Revision Date: 10.10.2020 SDS Number: 49927-00015 Date of last issue: 13.09.2019
Date of first issue: 26.01.2015

workplace.
Wash contaminated clothing before re-use.

Conditions for safe storage : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.
Store in accordance with the particular national regulations.

Materials to avoid : Do not store with the following product types:
Strong oxidizing agents

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parameters / Permissible concentration	Basis
Cellulose	9004-34-6	TWA	10 mg/m ³	AU OEL
	Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica			
		TWA	10 mg/m ³	ACGIH
Losartan	124750-99-8	TWA	100 µg/m ³ (OEB 2)	Internal
Amlodipine Besylate	652969-01-2	TWA	20 µg/m ³ (OEB 3)	Internal
		Wipe limit	100 µg/100 cm ²	Internal
Titanium dioxide	13463-67-7	TWA	10 mg/m ³	AU OEL
	Further information: This value is for inhalable dust containing no asbestos and < 1% crystalline silica			
		TWA	10 mg/m ³ (Titanium dioxide)	ACGIH

Engineering measures : Minimize workplace exposure concentrations.
Apply measures to prevent dust explosions.
Ensure that dust-handling systems (such as exhaust ducts, dust collectors, vessels, and processing equipment) are designed in a manner to prevent the escape of dust into the work area (i.e., there is no leakage from the equipment).
If sufficient ventilation is unavailable, use with local exhaust ventilation.

Personal protective equipment

Respiratory protection : If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.

Filter type : Particulates type

Hand protection

Material : Chemical-resistant gloves

Remarks : Choose gloves to protect hands against chemicals depending on the concentration and quantity of the hazardous substance and specific to place of work. Breakthrough time is not determined for the product. Change gloves often! For special applications, we recommend clarifying the resistance to chemicals of the aforementioned protective gloves with the

SAFETY DATA SHEET



Losartan / Amlodipine Besylate Formulation



Version 3.11 Revision Date: 10.10.2020 SDS Number: 49927-00015 Date of last issue: 13.09.2019
Date of first issue: 26.01.2015

Eye protection : glove manufacturer. Wash hands before breaks and at the end of workday.
: Wear the following personal protective equipment:
Chemical resistant goggles must be worn.
If splashes are likely to occur, wear:
Face-shield

Skin and body protection : Select appropriate protective clothing based on chemical resistance data and an assessment of the local exposure potential.
Skin contact must be avoided by using impervious protective clothing (gloves, aprons, boots, etc).

SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance : powder

Colour : No data available

Odour : No data available

Odour Threshold : No data available

pH : No data available

Melting point/freezing point : No data available

Initial boiling point and boiling range : No data available

Flash point : Not applicable

Evaporation rate : No data available

Flammability (solid, gas) : May form explosive dust-air mixture during processing, handling or other means.

Flammability (liquids) : No data available

Upper explosion limit / Upper flammability limit : No data available

Lower explosion limit / Lower flammability limit : No data available

Vapour pressure : No data available

Relative vapour density : No data available

Relative density : No data available

Density : No data available

Solubility(ies)
Water solubility : No data available

SAFETY DATA SHEET



Losartan / Amlodipine Besylate Formulation



Version 3.11 Revision Date: 10.10.2020 SDS Number: 49927-00015 Date of last issue: 13.09.2019
Date of first issue: 26.01.2015

Partition coefficient: n-octanol/water : No data available
Auto-ignition temperature : No data available
Decomposition temperature : No data available
Viscosity
 Viscosity, kinematic : No data available
Explosive properties : Not explosive
Oxidizing properties : The substance or mixture is not classified as oxidizing.
Molecular weight : No data available
Particle size : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : Not classified as a reactivity hazard.
Chemical stability : Stable under normal conditions.
Possibility of hazardous reactions : May form explosive dust-air mixture during processing, handling or other means.
Can react with strong oxidizing agents.
Conditions to avoid : Heat, flames and sparks.
Avoid dust formation.
Incompatible materials : Oxidizing agents
Hazardous decomposition products : No hazardous decomposition products are known.

SECTION 11. TOXICOLOGICAL INFORMATION

Exposure routes : Inhalation
Skin contact
Ingestion
Eye contact

Acute toxicity

Not classified based on available information.

Product:

Acute oral toxicity : Acute toxicity estimate: > 5,000 mg/kg
Method: Expert judgement

Components:

Cellulose:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity : LC50 (Rat): > 5.8 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Losartan / Amlodipine Besylate Formulation

Version 3.11 Revision Date: 10.10.2020 SDS Number: 49927-00015 Date of last issue: 13.09.2019
Date of first issue: 26.01.2015

Acute dermal toxicity : LD50 (Rabbit): > 2,000 mg/kg

Losartan:

Acute oral toxicity : LD50 (Mouse): 1,257 - 1,590 mg/kg

LDLo (Rat): 200 mg/kg

LDLo (Mouse): 400 mg/kg

Amlodipine Besylate:

Acute oral toxicity : LD50 (Rat): 393 mg/kg

Titanium dioxide:

Acute oral toxicity : LD50 (Rat): > 5,000 mg/kg

Acute inhalation toxicity : LC50 (Rat): > 6.82 mg/l

Exposure time: 4 h

Test atmosphere: dust/mist

Assessment: The substance or mixture has no acute inhalation toxicity

Skin corrosion/irritation

Not classified based on available information.

Components:**Losartan:**

Species : Rabbit

Result : Mild skin irritation

Titanium dioxide:

Species : Rabbit

Result : No skin irritation

Serious eye damage/eye irritation

Causes serious eye damage.

Components:**Losartan:**

Species : Rabbit

Result : Severe irritation

Amlodipine Besylate:

Species : Rabbit

Result : Severe irritation

Titanium dioxide:

Species : Rabbit

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	10.10.2020	49927-00015	Date of first issue: 26.01.2015

Result : No eye irritation

Respiratory or skin sensitisation**Skin sensitisation**

May cause an allergic skin reaction.

Respiratory sensitisation

Not classified based on available information.

Components:**Losartan:**

Test Type	: Maximisation Test
Exposure routes	: Skin contact
Species	: Guinea pig
Assessment	: Probability or evidence of skin sensitisation in humans
Result	: positive

Titanium dioxide:

Test Type	: Local lymph node assay (LLNA)
Exposure routes	: Skin contact
Species	: Mouse
Result	: negative

Chronic toxicity**Germ cell mutagenicity**

Not classified based on available information.

Components:**Cellulose:**

Genotoxicity in vitro	:	Test Type: Bacterial reverse mutation assay (AMES)
		Result: negative
		Test Type: In vitro mammalian cell gene mutation test
		Result: negative
Genotoxicity in vivo	:	Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
		Species: Mouse
		Application Route: Ingestion
		Result: negative

Losartan:

Genotoxicity in vitro	:	Test Type: in vitro assay
		Result: negative
		Test Type: In vitro mammalian cell gene mutation test
		Test system: Chinese hamster ovary cells
		Result: negative
		Test Type: Alkaline elution assay

Losartan / Amlodipine Besylate Formulation

Version 3.11 Revision Date: 10.10.2020 SDS Number: 49927-00015 Date of last issue: 13.09.2019
Date of first issue: 26.01.2015

Result: negative

Test Type: Chromosomal aberration

Result: negative

Genotoxicity in vivo : Test Type: Chromosomal aberration
Result: negative

Amlodipine Besylate:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosome aberration test in vitro

Result: negative

Titanium dioxide:

Genotoxicity in vitro : Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Genotoxicity in vivo : Test Type: In vivo micronucleus test
Species: Mouse
Result: negative

Carcinogenicity

Not classified based on available information.

Components:**Cellulose:**

Species : Rat
Application Route : Ingestion
Exposure time : 72 weeks
Result : negative

Losartan:

Species : Mouse
Application Route : Oral
Exposure time : 92 weeks
Dose : 200 mg/kg body weight
Result : negative

Species : Rat
Application Route : Oral
Exposure time : 105 weeks
Dose : 270 mg/kg body weight
Result : negative

Amlodipine Besylate:

Species : Mouse
Application Route : Oral
Exposure time : 2 Years
Result : negative

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	10.10.2020	49927-00015	Date of first issue: 26.01.2015

Species : Rat
 Application Route : Oral
 Exposure time : 2 Years
 Result : negative

Titanium dioxide:

Species : Rat
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 2 Years
 Method : OECD Test Guideline 453
 Result : positive
 Remarks : The mechanism or mode of action may not be relevant in humans.

Carcinogenicity - Assessment : Limited evidence of carcinogenicity in inhalation studies with animals.

Reproductive toxicity

May damage the unborn child.
 May cause harm to breast-fed children.

Components:**Cellulose:**

Effects on fertility : Test Type: One-generation reproduction toxicity study
 Species: Rat
 Application Route: Ingestion
 Result: negative

Effects on foetal development : Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Ingestion
 Result: negative

Losartan:

Effects on fertility : Test Type: Fertility
 Species: Rat, female
 Application Route: Oral
 Fertility: LOAEL: 200 mg/kg body weight
 Result: female reproductive effects
 Remarks: Maternal toxicity observed.

Effects on foetal development : Test Type: Development
 Species: Rabbit
 Application Route: Oral
 General Toxicity Maternal: NOAEL: 10 mg/kg body weight
 Developmental Toxicity: NOAEL F1: 20 mg/kg body weight
 Result: Embryotoxic effects and adverse effects on the offspring were detected only at high maternally toxic doses, No teratogenic effects

Test Type: Development

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	10.10.2020	49927-00015	Date of first issue: 26.01.2015

Species: Rat
 Application Route: Oral
 Developmental Toxicity: LOAEL: 10 mg/kg body weight
 Result: Fetotoxicity, No teratogenic effects

Reproductive toxicity - Assessment : Clear evidence of adverse effects on development, based on animal experiments.

Studies indicating a hazard to babies during the lactation period

Amlodipine Besylate:

Effects on fertility : Test Type: Fertility/early embryonic development
 Species: Rat
 Application Route: Ingestion
 Fertility: NOAEL: 10 mg/kg body weight
 Result: No effects on fertility

Test Type: Fertility/early embryonic development
 Species: Rabbit
 Application Route: Ingestion
 Fertility: NOAEL: 25 mg/kg body weight
 Result: No effects on fertility

Effects on foetal development : Test Type: Embryo-foetal development
 Species: Rat
 Application Route: Ingestion
 Developmental Toxicity: LOAEL: 10 mg/kg body weight
 Result: Effects on foetal development

Test Type: Embryo-foetal development
 Species: Rabbit
 Application Route: Ingestion
 Developmental Toxicity: NOAEL: 10 mg/kg body weight
 Result: No effects on foetal development

Test Type: Embryo-foetal development
 Species: Mouse
 Application Route: Ingestion
 Developmental Toxicity: LOAEL: 1.6 mg/kg body weight
 Result: Effects on foetal development
 Remarks: Maternal toxicity observed.

STOT - single exposure

Not classified based on available information.

STOT - repeated exposure

May cause damage to organs (Blood, Cardio-vascular system, Stomach, Kidney) through prolonged or repeated exposure if swallowed.

Components:**Losartan:**

Exposure routes : Ingestion

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	10.10.2020	49927-00015	Date of first issue: 26.01.2015

Target Organs : Blood, Cardio-vascular system, Stomach, Kidney
 Assessment : May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****Cellulose:**

Species : Rat
 NOAEL : >= 9,000 mg/kg
 Application Route : Ingestion
 Exposure time : 90 Days

Losartan:

Species : Rat
 LOAEL : 15 mg/kg
 Application Route : Oral
 Exposure time : 309 d
 Number of exposures : daily
 Target Organs : Blood, Kidney, Cardio-vascular system, Stomach

Species : Dog
 NOAEL : 5 mg/kg
 Application Route : Oral
 Exposure time : 1 Months
 Symptoms : Salivation, Vomiting

Species : Dog
 LOAEL : 25 mg/kg
 Application Route : Oral
 Exposure time : 53 Weeks
 Number of exposures : daily
 Symptoms : Salivation, Vomiting

Amlodipine Besylate:

Species : Rat
 NOAEL : 15 mg/kg
 Application Route : Oral
 Exposure time : 90 d
 Remarks : No significant adverse effects were reported

Titanium dioxide:

Species : Rat
 NOAEL : 24,000 mg/kg
 Application Route : Ingestion
 Exposure time : 28 Days

Species : Rat
 NOAEL : 10 mg/m³
 Application Route : inhalation (dust/mist/fume)
 Exposure time : 2 yr

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	10.10.2020	49927-00015	Date of first issue: 26.01.2015

Aspiration toxicity

Not classified based on available information.

Components:**Losartan:**

No aspiration toxicity classification

Experience with human exposure**Components:****Losartan:**

Eye contact	:	Symptoms: Eye irritation
Ingestion	:	Symptoms: hypotension, tachycardia

Amlodipine Besylate:

Eye contact	:	Symptoms: Severe irritation
Ingestion	:	Symptoms: Nausea, Abdominal pain, Fatigue, Headache, Oedema, Palpitation

SECTION 12. ECOLOGICAL INFORMATION**Ecotoxicity****Components:****Cellulose:**

Toxicity to fish	:	LC50 (<i>Oryzias latipes</i> (Japanese medaka)): > 100 mg/l Exposure time: 48 h Remarks: Based on data from similar materials
------------------	---	--

Losartan:

Toxicity to fish	:	LC50 (<i>Oncorhynchus mykiss</i> (rainbow trout)): > 929 mg/l Exposure time: 96 h Method: FDA 4.11
------------------	---	---

Toxicity to daphnia and other aquatic invertebrates	:	EC50 (<i>Daphnia magna</i> (Water flea)): 331 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
---	---	---

Toxicity to algae/aquatic plants	:	NOEC (<i>Microcystis aeruginosa</i> (blue-green algae)): 949 mg/l Exposure time: 10 d Method: FDA 4.01
----------------------------------	---	---

	:	NOEC (<i>Selenastrum capricornutum</i> (green algae)): 143 mg/l Exposure time: 10 d Method: FDA 4.01
--	---	---

Toxicity to fish (Chronic toxicity)	:	NOEC (<i>Pimephales promelas</i> (fathead minnow)): 10 mg/l Exposure time: 32 d Method: OECD Test Guideline 210
-------------------------------------	---	--

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	10.10.2020	49927-00015	Date of first issue: 26.01.2015

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 100 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Amlodipine Besylate:

Toxicity to fish : LC50 (Pimephales promelas (fathead minnow)): 2.7 mg/l
Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 3.2 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : IC50 (Pseudokirchneriella subcapitata (green algae)): 5.6 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

Titanium dioxide:

Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h

Toxicity to algae/aquatic plants : EC50 (Skeletonema costatum (marine diatom)): > 10,000 mg/l
Exposure time: 72 h

Toxicity to microorganisms : EC50: > 1,000 mg/l
Exposure time: 3 h
Method: OECD Test Guideline 209

Persistence and degradability**Components:****Cellulose:**

Biodegradability : Result: Readily biodegradable.

Losartan:

Stability in water : Hydrolysis: < 10 %(5 d)

Bioaccumulative potential**Components:****Losartan:**

Partition coefficient: n-octanol/water : log Pow: 1.2

Amlodipine Besylate:

Partition coefficient: n-octanol/water : log Pow: 3

Losartan / Amlodipine Besylate Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	10.10.2020	49927-00015	Date of first issue: 26.01.2015

Mobility in soil

No data available

Other adverse effectsNo data available

SECTION 13. DISPOSAL CONSIDERATIONS**Disposal methods**

Waste from residues	:	Dispose of in accordance with local regulations.
Contaminated packaging	:	Empty containers should be taken to an approved waste handling site for recycling or disposal. If not otherwise specified: Dispose of as unused product.

SECTION 14. TRANSPORT INFORMATION**International Regulations****UNRTDG**

Not regulated as a dangerous good

IATA-DGR

Not regulated as a dangerous good

IMDG-Code

Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

National Regulations**ADG**Not regulated as a dangerous good

SECTION 15. REGULATORY INFORMATION**Safety, health and environmental regulations/legislation specific for the substance or mixture**

Prohibition/Licensing Requirements	:	There is no applicable prohibition, authorisation and restricted use requirements, including for carcinogens referred to in Schedule 10 of the model WHS Act and Regulations.
------------------------------------	---	---

The components of this product are reported in the following inventories:

AICS	:	not determined
DSL	:	not determined
IECSC	:	not determined

SAFETY DATA SHEET



Losartan / Amlodipine Besylate Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	10.10.2020	49927-00015	Date of first issue: 26.01.2015

SECTION 16. OTHER INFORMATION

Further information

Revision Date : 10.10.2020
Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>
Date format : dd.mm.yyyy

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
AU OEL : Australia. Workplace Exposure Standards for Airborne Contaminants.
ACGIH / TWA : 8-hour, time-weighted average
AU OEL / TWA : Exposure standard - time weighted average

AllC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS mate-

SAFETY DATA SHEET



Losartan / Amlodipine Besylate Formulation



Version	Revision Date:	SDS Number:	Date of last issue: 13.09.2019
3.11	10.10.2020	49927-00015	Date of first issue: 26.01.2015

Material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

AU / EN